Financials · Insurance Agents, Brokers & Service

SLQT SelectQuote, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 179478362 filings
Russell 2000

SLQT at a glance

SelectQuote, Inc. (SLQT, SEC CIK 1794783) filed its latest 10-K annual report on August 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2026 (FY2026), SelectQuote, Inc. (SLQT) reported revenue of $1.6 billion (up 6.0% from FY2025) and net income of $62.2 million. Diluted EPS was -$0.06.
  • As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding SelectQuote, Inc. (SLQT) shares worth $5.7 million in 13F-HR filings.
  • In the last 90 days, SLQT insiders reported 6 open-market purchases ($446K) and 0 open-market sales ($0) on Form 4, a net purchase of $446K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$1.6B
+6.0% vs prior year
Insiders · 90 days
6 buys · 0 sells
Net +$446K
13F holders
20 funds
$5.7M · −5 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01 · Item 3.03 · Item 5.03 · Item 5.07

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Business Overview

  • Core business: Technology-enabled direct-to-consumer platform distributing insurance policies and expanding healthcare services for seniors
  • New emphasis on Healthcare Services segment including SelectRx pharmacy, Healthcare Select engagement, and SelectPatient Management chronic care launched in 2024
  • Strategic shift away from Auto & Home insurance focus toward higher-growth healthcare and senior insurance segments leveraging AI technology
  • Employee base as of June 30, 2026: 1,098 agents and 2,941 non-agent full-time equivalents; hired approx. 814 seasonal employees for 2025 AEP
  • Opened new SelectRx fulfillment facility in April 2025, expanding prescription capacity enabling service to over 200,000 members with room to grow

Risk Factors

  • DOJ False Claims Act complaint filed May 2025 alleging violations in Medicare marketing could materially harm operations and financial condition
  • Geographic concentration risk with 39%, 13%, 12% of 2026 revenue from UHC, Humana, Aetna exposing dependency on few insurers
  • Supply chain disruption risk for pharmacy business due to delays in prescription acquisition and manufacture, impacting service and growth
  • Competitive pressure risks from insurance carriers’ direct sales channels and platforms like government-run health insurance exchanges
  • NYSE delisting risk due to stock price under $1.00, with planned reverse stock split to regain compliance by April 2027 deadline

Management Discussion & Analysis

  • Revenue $1.62B, up 6% YoY from $1.53B in FY2025; commissions and other services down 1% to $788M, pharmacy up 14% to $831M
  • Operating income $73.9M, net income $62.2M vs $48.5M income and $47.6M net income FY2025; effective tax rate 18.5% vs 1.9%
  • Best segment Healthcare Services revenue $845M (+14%), adjusted EBITDA $25.5M (+0.1M); worst Senior revenue $576M (-4%), adjusted EBITDA $148M (-$13.6M)
  • Net cash from operations $31.9M vs $(11.7)M; capex $16.1M; financing outflows $31.1M mainly debt repayments; cash $21.7M vs $37.1M
  • Management outlook implies focus on AI investments for agent productivity, healthcare services growth, and maintaining debt covenant compliance; risk from policy retention and Inflation Reduction Act impact on pharmacy margins

AI summary of the SLQT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to Annual Report risk factors disclosed this quarter
  • Carried-forward business risk: known and unknown risks could materially harm operations
  • Carried-forward financial risk: identified risks could materially impair financial condition
  • Carried-forward investor risk: risk realization could adversely affect securities value

Management Discussion & Analysis

  • Revenue $280.0M, down 15% YoY from $328.8M, including pharmacy revenue down 16% to $184.0M
  • Net loss $20.3M vs $30.5M; operating margin (10%) vs (12%) YoY, net margin (7%) vs (9%)
  • Healthcare Services largest segment at $186.3M revenue, down 16%; Senior weakest Adjusted EBITDA at $(12.3)M
  • Cash, equivalents and restricted cash $14.3M vs $21.7M; operating cash use $17.2M, investing cash use $3.6M
  • Management expects existing cash, revolver availability and operating cash to fund working capital, investments and debt service; SelectRx members down 7% with profitability per member up 60%

AI summary of the SLQT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Reverse stock split announced November 13, 2026, changing SelectQuote’s share count and per-share trading basis
  • Split-adjusted trading and fractional-share treatment may affect shareholder holdings and liquidity

Item 3.03: Material Modification to Rights of Security Holders

  • Item 3.03 points to Item 5.03 for details on amendments affecting SelectQuote security-holder rights
  • Investor impact depends on the specific charter or bylaw changes described in Item 5.03

Item 5.03: Amendments to Articles of Incorporation or Bylaws

  • 1-for-20 reverse stock split effective 11:59 p.m. ET November 16, 2026
  • Objective: raise per-share price to regain NYSE continued-listing compliance

Item 5.07: Submission of Matters to a Vote of Security Holders

  • 106.6M of 179.3M shares represented, providing quorum for all proposals
  • All three Class I directors elected through 2029, with Kavita Patel receiving lower support than peers

Item EX-99.1: Item EX-99.1

  • 1-for-20 reverse split effective November 16, 2026, with split-adjusted trading November 17 under SLQT
  • Primary objective: regain compliance with NYSE minimum stock-price requirements and preserve exchange listing
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal Q1 2026 results cover the quarter ended September 30, 2026
  • Press release and investor presentation provide the financial results and management commentary

Item EX-99.2: Item EX-99.2

  • 1Q FY27 revenue $280M, down 15% year-over-year, primarily reflecting Inflation Reduction Act pressure on Healthcare Services
  • Adjusted EBITDA $(17)M versus $(32)M, a $15M year-over-year improvement driven by Healthcare Services profitability and lower Senior investment

Item EX-99.1: Item EX-99.1

  • Q1 FY2027 revenue fell 15% to $280.0 million, but net loss improved to $20.3 million from $30.5 million
  • Adjusted EBITDA loss narrowed to $17.0 million from $32.1 million, signaling meaningful cost discipline despite lower sales
Filed Aug 25, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal Q4 2026 results reported for quarter ended June 30, 2026
  • Press release and investor presentation provide detailed financial results and management commentary

Item EX-99.2: Item EX-99.2

  • FY2026 revenue $1.618B, up from $1.527B, while Adjusted EBITDA declined to $109M from $126M
  • Operating cash flow improved to $32M from $(12)M, a $44M year-over-year gain supporting liquidity

Item EX-99.1: Item EX-99.1

  • Q4 revenue $321.7M, down from $345.1M, while Adjusted EBITDA rose to $11.9M from $2.7M
  • FY2026 revenue $1.6B and net income $62.2M, but Adjusted EBITDA declined to $109.1M from $126.3M

AI summaries of SLQT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SLQT

Don't miss the next SLQT filing

  • Alerts as it files. A push when SLQT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SLQT, by share count.
  • Ask anything. An AI agent that reads every SLQT filing and answers with sources.

SLQT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Devine Denise LANov 10, 2026-
DEVANNY EARL H IIIANov 10, 2026-
Hawks Donald L IIIANov 10, 2026-
Devine Denise LMNov 10, 2026-
DEVANNY EARL H IIIMNov 10, 2026-
DEVANNY EARL H IIIMNov 10, 2026-
Hawks Donald L IIIMNov 10, 2026-
Hawks Donald L IIIMNov 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$1.5B$1.6B
Operating Income$64.5M$68.5M$73.9M
Net Income-$34.1M$47.6M$62.2M
Op. Margin-4.5%4.6%
Net Margin-3.1%3.8%
Balance Sheet
Total Assets-$1.2B$1.3B
Equity-$351.1M$351.8M
ROE-13.5%17.7%
Per Share
EPS$-0.20$0.01$-0.06
Cash Flow
Operating CF--$11.7M$31.9M
CapEx$3.4M$2.2M$4.3M

Source: XBRL data in SelectQuote, Inc. (SLQT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SLQT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SLQT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202620$5.7M
Q2 202625$15.9M
Q1 202626$19.2M
Q4 202527$45.5M
Q3 202527$64.0M
Q2 202528$84.3M
Q1 202525$74.8M
Q4 202418$58.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 196 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SLQT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
10-KAug 25, 2026Analysis
8-KAug 25, 2026Analysis-
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--
4Aug 4, 2026--

Related Financials companies

All Financials →

SLQT SEC filings: frequently asked questions

Are SLQT insiders buying or selling?

In the last 90 days, SelectQuote, Inc. (SLQT) officers, directors and 10% owners reported 6 open-market purchases worth $446,272 by 5 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold SLQT stock?

As of September 30, 2026, the largest SelectQuote, Inc. (SLQT) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($2.5 million), BlackRock ($809,000), Millennium Management ($411,000), State Street Corp ($275,000), Renaissance Technologies LLC ($270,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SLQT's revenue in fiscal year 2026?

For the fiscal year ended June 30, 2026 (FY2026), SelectQuote, Inc. (SLQT) reported revenue of $1.6 billion (up 6.0% from FY2025) and net income of $62.2 million. Diluted EPS was -$0.06. The figures come from the XBRL data in the 10-K.

What are the main risks in SLQT's latest 10-K?

In the 10-K filed August 25, 2026, SelectQuote, Inc. (SLQT) flagged: DOJ False Claims Act complaint filed May 2025 alleging violations in Medicare marketing could materially harm operations and financial condition. Geographic concentration risk with 39%, 13%, 12% of 2026 revenue from UHC, Humana, Aetna exposing dependency on few insurers. (AI summary of the Risk Factors section.)

What did SLQT report in its latest 8-K?

SelectQuote, Inc. (SLQT) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.03 (Amendments to Articles of Incorporation or Bylaws) and Item 5.07 (Submission of Matters to a Vote of Security Holders). Reverse stock split announced November 13, 2026, changing SelectQuote’s share count and per-share trading basis.

What are the latest SLQT SEC filings?

SelectQuote, Inc. (SLQT) filed its latest 10-K annual report on August 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 13, 2026.

What is SLQT's SEC CIK number?

SelectQuote, Inc. (SLQT)'s SEC Central Index Key (CIK) is 1794783. EDGAR lists every SLQT filing under that number.

Ask anything about SLQT

The research agent reads SLQT's filings, financials, insider trades and 13F holders, then answers with sources.